<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="397">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108055</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-17472</org_study_id>
    <secondary_id>SU-04152010-5683</secondary_id>
    <secondary_id>BLDR0010</secondary_id>
    <nct_id>NCT01108055</nct_id>
  </id_info>
  <brief_title>Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer</brief_title>
  <official_title>A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandy Srinivas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor)&#xD;
      called pazopanib which is being studied in kidney cancer will be combined with standard&#xD;
      chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the results from the Phase 1 study of pazopanib combined with paclitaxel and the&#xD;
      activity of paclitaxel in urothelial cancer, testing this regimen in a disease where there is&#xD;
      an unmet need appears appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>The tumor response rate was assessed per the Response Evaluation Criteria In Solid Tumors (RECIST). RECIST criteria are a set of published rules that define when cancer patients improve (&quot;respond&quot;); stay the same (&quot;stable&quot;); or worsen (&quot;progression&quot;) during treatments. RECIST criteria offer a simplified and conservative extraction of imaging data suitable for wide application in clinical trials. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:&#xD;
Complete response (CR) = Disappearance of all target lesions&#xD;
Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions&#xD;
Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions&#xD;
Stable disease (SD) = Small changes that do not meet above criteria Objective tumor response means those with response better than stable disease, ie, complete response (CR) + partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>4 years</time_frame>
    <description>The tumor response rate was assessed per the Response Evaluation Criteria In Solid Tumors (RECIST). RECIST criteria are a set of published rules that define when cancer patients improve (&quot;respond&quot;); stay the same (&quot;stable&quot;); or worsen (&quot;progression&quot;) during treatments. RECIST criteria offer a simplified and conservative extraction of imaging data suitable for wide application in clinical trials. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:&#xD;
Complete response (CR) = Disappearance of all target lesions&#xD;
Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions&#xD;
Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions&#xD;
Stable disease (SD) = Small changes that do not meet above criteria Tumor response rate by each response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Overall survival is reported as the median survival of the evaluable subjects (ie, completed 2 cycles of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) by Bellmunt Score</measure>
    <time_frame>4 years</time_frame>
    <description>Comparison between the participant's baseline Bellmunt prognostic risk factor score and survival rates.&#xD;
The Bellmunt prognostic risk factor score is a tool that is often used to predict treatment outcomes before initiating a secondline treatment regimen.&#xD;
The risk factors used to calculate the Bellmunt score include:&#xD;
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1&#xD;
Presence of liver metastases&#xD;
Presence of visceral involvement (defined as liver, lung, bone or any non-lymph node)&#xD;
Lymph node-only involvement&#xD;
Hemoglobin concentration &lt; 10 g/dL&#xD;
The score is calculated based on the presence of 0; 1; 2; or 3 of the above prognostic factors. This outcome reports median overall survival based on whether the participant had 0; 1; 2; or 3 prognostic factors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Bladder (Urothelial, Transitional Cell) Cancer</condition>
  <condition>Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)</condition>
  <condition>Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)</condition>
  <condition>Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable</condition>
  <arm_group>
    <arm_group_label>pazopanib + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle of 28 days. Pazopanib: 800mg daily&#xD;
Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (GW786034)</intervention_name>
    <description>Cycle of 28 days. Pazopanib: 800mg/day</description>
    <arm_group_label>pazopanib + paclitaxel</arm_group_label>
    <other_name>GW786034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15</description>
    <arm_group_label>pazopanib + paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed transitional cell carcinoma (TCC) of the urothelium (bladder,&#xD;
             renal pelvis, ureter, or urethra). Mixed histology is allowed as long as the&#xD;
             predominant histology is TCC&#xD;
&#xD;
          2. First recurrence after treatment with a maximum of two chemotherapeutic regimens.&#xD;
&#xD;
          3. Subjects must provide written informed consent prior to performance of study-specific&#xD;
             procedures or assessments, and must be willing to comply with treatment and follow up.&#xD;
&#xD;
             Procedures conducted as part of the subject's routine clinical management (eg, blood&#xD;
             count, imaging study) and obtained prior to signing of informed consent may be&#xD;
             utilized for screening or baseline purposes provided these procedures are conducted as&#xD;
             specified in the protocol.&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          6. Measurable disease criteria by RECIST criteria&#xD;
&#xD;
          7. Adequate organ system function as defined below&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
               2. Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               3. Platelets ≥ 100 X 10^9/L&#xD;
&#xD;
               4. Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 x upper limit&#xD;
                  of normal (ULN)&#xD;
&#xD;
               5. Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               6. aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)≤ 2.5 x ULN&#xD;
&#xD;
               7. Serum creatinine ≤ 1.8 mg/dL&#xD;
&#xD;
               8. Urine Protein to Creatinine Ratio (UPC) &lt; 1&#xD;
&#xD;
          8. A female is eligible to enter and participate in this study if she is of&#xD;
             non-childbearing potential (ie, physiologically incapable of becoming pregnant). This&#xD;
             includes any female who has had:&#xD;
&#xD;
               -  A hysterectomy&#xD;
&#xD;
               -  A bilateral oophorectomy (ovariectomy)&#xD;
&#xD;
               -  A bilateral tubal ligation&#xD;
&#xD;
               -  Menopause&#xD;
&#xD;
        Childbearing potential females must have a negative serum pregnancy test within 2 weeks&#xD;
        prior to the first dose of study treatment, preferably as close to the first dose as&#xD;
        possible, and agree to use adequate contraception. Adequate acceptable contraceptive&#xD;
        methods, when used consistently and in accordance with both the product label and the&#xD;
        instructions of the physician, are as follow:&#xD;
&#xD;
          -  An intrauterine device with a documented failure rate of less than 1% per year.&#xD;
&#xD;
          -  Vasectomized partner who is sterile prior to the female subject's entry and is the&#xD;
             sole sexual partner for that female.&#xD;
&#xD;
          -  Complete abstinence from sexual intercourse for 14 days before exposure to&#xD;
             investigational product, through the dosing period, and for at least 21 days after the&#xD;
             last dose of investigational product.&#xD;
&#xD;
          -  Double-barrier contraception (condom with spermicidal jelly, foam suppository, or&#xD;
             film; diaphragm with spermicide; or male condom and diaphragm with spermicide).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other malignancies within 5 years prior to Day 1 except for tumors with a&#xD;
             negligible risk for metastasis or death, such as adequately controlled basal cell&#xD;
             carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix,&#xD;
             early-stage bladder cancer, or low-grade endometrial cancer Malignancies that have&#xD;
             undergone a putative surgical cure (ie, localized prostate cancer post-prostatectomy)&#xD;
             within 5 years prior to Day 1 may be discussed with the Medical Monitor&#xD;
&#xD;
          2. History or clinical evidence of central nervous system (CNS) metastases or&#xD;
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS&#xD;
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure&#xD;
             medication for 6 months prior to first dose of study drug.&#xD;
&#xD;
          3. Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             GI bleeding&#xD;
&#xD;
          4. Clinically significant gastrointestinal abnormalities that may affect absorption of&#xD;
             the investigational product&#xD;
&#xD;
          5. Presence of uncontrolled infection.&#xD;
&#xD;
          6. Prolongation of corrected QT interval (QTc) &gt; 480 milliseconds. On antiarrhythmics or&#xD;
             medications known to prolong QT interval&#xD;
&#xD;
          7. History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Coronary artery by-pass graft surgery&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
                  Association (NYHA)&#xD;
&#xD;
          8. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥ 140 mmHg&#xD;
             or diastolic blood pressure (DBP) of ≥ 90mm Hg].&#xD;
&#xD;
          9. History of cerebrovascular accident, hemoptysis, cerebral hemorrhage, clinically&#xD;
             significant GI bleed, pulmonary embolism or untreated deep venous thrombosis (DVT)&#xD;
             within the past 6 months&#xD;
&#xD;
         10. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or&#xD;
             presence of any non-healing wound, fracture&#xD;
&#xD;
         11. Evidence of active bleeding or bleeding diathesis.&#xD;
&#xD;
         12. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
             could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
             procedures.&#xD;
&#xD;
         13. Patients on strong CYP3A4 inhibitors&#xD;
&#xD;
         14. Uncorrected abnormal electrolytes: K, Mg and Ca&#xD;
&#xD;
         15. Prior treatment with taxane chemotherapy&#xD;
&#xD;
         16. Treatment with any of the following anti-cancer therapies:&#xD;
&#xD;
               -  radiation therapy, surgery or tumor embolization within 14 days prior to the&#xD;
                  first dose of pazopanib OR&#xD;
&#xD;
               -  chemotherapy, immunotherapy, biologic therapy, investigational therapy or&#xD;
                  hormonal therapy within 14 days or five half-lives of a drug (whichever is&#xD;
                  longer) prior to the first dose of pazopanib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sandy Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2017</results_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandy Srinivas</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pazopanib + Paclitaxel</title>
          <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not evaluable- didn't complete treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pazopanib + Paclitaxel</title>
          <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="29" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Treatment Cycles</title>
          <description>A full treatment cycle is defined as 28 days.</description>
          <units>Cycles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sites of Primary Tumor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bladder</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Renal Pelvis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ureter</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of prior chemotherapies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from last chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bellmunt Score</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response</title>
        <description>The tumor response rate was assessed per the Response Evaluation Criteria In Solid Tumors (RECIST). RECIST criteria are a set of published rules that define when cancer patients improve (&quot;respond&quot;); stay the same (&quot;stable&quot;); or worsen (&quot;progression&quot;) during treatments. RECIST criteria offer a simplified and conservative extraction of imaging data suitable for wide application in clinical trials. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:&#xD;
Complete response (CR) = Disappearance of all target lesions&#xD;
Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions&#xD;
Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions&#xD;
Stable disease (SD) = Small changes that do not meet above criteria Objective tumor response means those with response better than stable disease, ie, complete response (CR) + partial response (PR).</description>
        <time_frame>Every 8 weeks</time_frame>
        <population>The outcome is reported as subjects with CR (complete response) + PR (partial response).</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib + Paclitaxel</title>
            <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response</title>
          <description>The tumor response rate was assessed per the Response Evaluation Criteria In Solid Tumors (RECIST). RECIST criteria are a set of published rules that define when cancer patients improve (&quot;respond&quot;); stay the same (&quot;stable&quot;); or worsen (&quot;progression&quot;) during treatments. RECIST criteria offer a simplified and conservative extraction of imaging data suitable for wide application in clinical trials. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:&#xD;
Complete response (CR) = Disappearance of all target lesions&#xD;
Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions&#xD;
Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions&#xD;
Stable disease (SD) = Small changes that do not meet above criteria Objective tumor response means those with response better than stable disease, ie, complete response (CR) + partial response (PR).</description>
          <population>The outcome is reported as subjects with CR (complete response) + PR (partial response).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib + Paclitaxel</title>
            <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.6" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>The tumor response rate was assessed per the Response Evaluation Criteria In Solid Tumors (RECIST). RECIST criteria are a set of published rules that define when cancer patients improve (&quot;respond&quot;); stay the same (&quot;stable&quot;); or worsen (&quot;progression&quot;) during treatments. RECIST criteria offer a simplified and conservative extraction of imaging data suitable for wide application in clinical trials. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:&#xD;
Complete response (CR) = Disappearance of all target lesions&#xD;
Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions&#xD;
Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions&#xD;
Stable disease (SD) = Small changes that do not meet above criteria Tumor response rate by each response criteria.</description>
        <time_frame>4 years</time_frame>
        <population>Does not include participants who did not complete 2 cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib + Paclitaxel</title>
            <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>The tumor response rate was assessed per the Response Evaluation Criteria In Solid Tumors (RECIST). RECIST criteria are a set of published rules that define when cancer patients improve (&quot;respond&quot;); stay the same (&quot;stable&quot;); or worsen (&quot;progression&quot;) during treatments. RECIST criteria offer a simplified and conservative extraction of imaging data suitable for wide application in clinical trials. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:&#xD;
Complete response (CR) = Disappearance of all target lesions&#xD;
Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions&#xD;
Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions&#xD;
Stable disease (SD) = Small changes that do not meet above criteria Tumor response rate by each response criteria.</description>
          <population>Does not include participants who did not complete 2 cycles of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is reported as the median survival of the evaluable subjects (ie, completed 2 cycles of treatment).</description>
        <time_frame>4 years</time_frame>
        <population>Does not include participants who did not complete 2 cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib + Paclitaxel</title>
            <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is reported as the median survival of the evaluable subjects (ie, completed 2 cycles of treatment).</description>
          <population>Does not include participants who did not complete 2 cycles of treatment.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5.7" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) by Bellmunt Score</title>
        <description>Comparison between the participant's baseline Bellmunt prognostic risk factor score and survival rates.&#xD;
The Bellmunt prognostic risk factor score is a tool that is often used to predict treatment outcomes before initiating a secondline treatment regimen.&#xD;
The risk factors used to calculate the Bellmunt score include:&#xD;
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1&#xD;
Presence of liver metastases&#xD;
Presence of visceral involvement (defined as liver, lung, bone or any non-lymph node)&#xD;
Lymph node-only involvement&#xD;
Hemoglobin concentration &lt; 10 g/dL&#xD;
The score is calculated based on the presence of 0; 1; 2; or 3 of the above prognostic factors. This outcome reports median overall survival based on whether the participant had 0; 1; 2; or 3 prognostic factors.</description>
        <time_frame>4 years</time_frame>
        <population>Include all 32 participants, regardless of completing 2 cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib + Paclitaxel</title>
            <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS) by Bellmunt Score</title>
          <description>Comparison between the participant's baseline Bellmunt prognostic risk factor score and survival rates.&#xD;
The Bellmunt prognostic risk factor score is a tool that is often used to predict treatment outcomes before initiating a secondline treatment regimen.&#xD;
The risk factors used to calculate the Bellmunt score include:&#xD;
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1&#xD;
Presence of liver metastases&#xD;
Presence of visceral involvement (defined as liver, lung, bone or any non-lymph node)&#xD;
Lymph node-only involvement&#xD;
Hemoglobin concentration &lt; 10 g/dL&#xD;
The score is calculated based on the presence of 0; 1; 2; or 3 of the above prognostic factors. This outcome reports median overall survival based on whether the participant had 0; 1; 2; or 3 prognostic factors.</description>
          <population>Include all 32 participants, regardless of completing 2 cycles of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bellmunt Score of 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="6" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bellmunt Score of 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bellmunt Score of 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bellmunt Score of 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pazopanib + Paclitaxel</title>
          <description>A trial combining paclitaxel with pazopanib, a commonly used anti-angiogenic agent with significant anti-tumor activity in various solid tumors.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>infection with grade 3 or 4 neutrophils</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>bacterial pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>infection with normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>wound complication, non infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lukocytes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hemolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients without baseline audiogram and not enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="ctcae3">anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis - oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>salivary gland changes/saliva</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>GI, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hemorrhage, GI - Varices</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="35" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pain, back</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain, abdomen NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain, head/headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain, chest/thorax NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain Extremity-limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain, chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain, oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>growth and development- other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>infection with unknown ANC - Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine, increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Alt, SGPT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration rate</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>muscle weakness, extraocular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>muscle weakness, whole body/generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cognitive distrubance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>memory impariment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mood alteration - Anxeity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hemorrhage, GU - bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU - Urinary NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>gynecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Nose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>diaphoresis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>vascular - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandy Srinivas, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650 498 6000</phone>
      <email>sandysri@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

